Trial of malaria vaccine plus drugs confirms two-thirds reduction in infections, deaths

Malaria
Malaria kills sign

Ken Doerr / Flickr cc

The final results of a phase 3 trial on the combination of a seasonal malaria vaccine and antimalarial drugs in children confirms a two-thirds decrease in the mosquito-borne illness, including severe cases and deaths, over 5 years in Burkina Faso and Mali.

Yesterday in The Lancet Infectious Diseases, a team led by researchers from the University of Science, Technology and Techniques of Bamako (USTTB) in Mali describe the comparison of seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine and amodiaquine plus control vaccines, the RTS,S/AS01E vaccine plus placebo SMC, or SMC plus RTS,S/AS01E.

The World Health Organization (WHO) recommends monthly SMC during the rainy season, when malaria transmission peaks. GlaxoSmithKline's circumsporozoite protein-based RTS,S/AS01E vaccine is licensed for malarial control in Africa. Circumsporozoite protein is the antigenic target of the vaccine.

Superior to preventive drugs, vaccine alone

Children enrolled in the initial 3-year trial at ages 5 to 17 months in 2017 were randomly assigned to receive one of the three interventions until they were 5 years old. In the phase 3 trial, children randomly assigned to receive the RTS,S/AS01E vaccine were vaccinated at months 0, 1, and 2, followed by a booster dose at month 20.

Non-inferiority was defined as a 20% increase in clinical malaria in the RTS,S/AS01E-alone group compared with the SMC-alone group, and superiority was defined as a 12% difference in the incidence of clinical malaria between the combined and single-intervention groups.

In April 2020, 5,098 (94%) of the 5,433 children who completed the initial 3-year follow-up were re-enrolled in the 2-year extension study. The incidence of clinical malaria per 1,000 person-years at risk over 5 years was 313 in the SMC-alone group, 320 in the RTS,S/AS01E-alone group, and 133 in the combination group.

The combination of RTS,S/AS01E and SMC was superior to SMC (protective efficacy, 57.7%) and to RTS,S/AS01E (protective efficacy, 59.0%) in preventing malaria. RTS,S/AS01E was non-inferior to SMC (hazard ratio, 1.03). The protective efficacy of the combination compared with SMC over 5 years was comparable to that observed in the first 3 years (protective efficacy of the combination vs SMC, 57.7% and vs RTS/AS01E-alone, 59.0%).

We can say that children who received the RTS,S-drug combination and also used bednets likely had greater than 90% protection against malaria episodes during the study.

Brian Greenwood, MD

In comparison, the respective protective efficacy during the first 3 years of the study was 62.8% and 59.6%. Hospitalizations fell for severe malaria (by 66.8%), malarial anemia (65.9%), blood transfusion (68.1%), all-cause death (44.5%), deaths excluding others causes or surgery (41.1%), and deaths from malaria (66.8%) in the combined group versus the SMC-alone group. No safety signals were identified.

Importance of multiple prevention tools

"We can say that children who received the RTS,S-drug combination and also used bednets likely had greater than 90% protection against malaria episodes during the study," senior author Brian Greenwood, MD, of the London School of Hygiene & Tropical Medicine, said in a PATH news release. "This points to the importance of ensuring access to multiple malaria prevention tools for reducing the tremendous burden of malaria disease and death in these highly seasonal settings."

Children in the study who received SMC and/or the vaccine are now being followed up for another 2 years. "The challenge now is to determine how best to deliver the vaccine-drug combination and to follow these highly protected children as they grow older," coauthor Jean-Bosco Ouedraogo, PhD, of Institut des Sciences et Techniques, said in the release.

In a related commentary, Sheetij Dutta, PhD, of Walter Reed Army Institute of Research, and Mahamadou Thera, MD, PhD, MPH, of USTTB, wrote, "Given the scarce resources available for malaria control, cost-effectiveness of this complex intervention tool, will need to be balanced against improved bednets, alternative SMC regimens, and future circumsporozoite protein-based interventions under investigation."

"Malaria burden has shifted to older children in areas where SMC has been effective since 2013," they added. "WHO has recommended to extend the age of SMC to older school-aged children. It remains to be established how the inclusion of RTS,S/AS01E will affect SMC effects at the population level."

This week's top reads

  1. 1 in 5 US retail milk samples test positive for H5N1 avian flu fragments

    The highest concentrations were in regions where the virus has been found in dairy herds.

    Lisa Schnirring
    grocery store milk

  2. Analysis of cow, cat H5N1 avian flu samples raises concerns about spread to other animals

    The cats started showing symptoms a day after clinical disease was noted in the cows, and about half of the cats died.

    Lisa Schnirring
    barn cat with milk pails

  3. Risk of uveitis recurrence higher in year after COVID vaccination

    The odds of the condition were increased among recipients of all 4 vaccines studied: Pfizer, Moderna, AstraZeneca, and J&J.

    Mary Van Beusekom

  4. USDA shares recent H5N1 avian flu sequences amid more dairy herd outbreaks

    In other developments, antiviral susceptibility testing shows that H5N1 is susceptible to neuraminidase inhibitor antiviral drugs.

    Lisa Schnirring
    woman in milking parlor

  5. Scientists find clues in early analysis of newly shared US H5N1 avian flu sequences

    Experts, with incomplete data, are quickly piecing together everything they can from the shared genetic sequences.

    Lisa Schnirring
    H5N1 particles

  6. WHO COVID vaccine advisers recommend switch to JN.1 strain

    The FDA's vaccine advisory group will discuss the make-up of 2024-25 vaccines at its meeting on May 16. 

    Lisa Schnirring
    vaccine prep

  7. H5N1 avian flu infects Colorado dairy cows as global experts weigh in on virus changes

    Global health groups say evolving developments, including a novel reassortant in Asia and increasing detections in mammals, require real-time monitoring.

    Lisa Schnirring
    dairy cow ear tags

  8. COVID may have eroded doctors' belief that they are obligated to treat infectious patients

    Reasons cited for accepting the option of refusing treatment included unreasonable risk to physicians and their families and labor rights and worker protection.

    Mary Van Beusekom
    Exhausted healthcare worker wearing N95

  9. USDA to test ground beef for traces of H5N1 avian flu virus as more poultry outbreaks reported

    Dairy cows make up about 7% of US beef production.

    Lisa Schnirring
    ground beef

  10. US orders testing for certain dairy cows after H5N1 avian flu remnants found in retail milk

    The USDA says that lactating dairy cows must be tested before interstate transport.

    Lisa Schnirring
    Cows exiting truck